BIOMARIN PHARMACEUTICAL ($BMRN) posted quarterly earnings results for Q4 2025 on Monday, February 23rd. The company reported earnings of $0.46 per share, missing estimates of $0.64 by $0.18. The company also reported revenue of $874,570,000, beating estimates of $844,444,658 by $30,125,342.
Stock price change since market close: -2.46%
You can see Quiver Quantitative's $BMRN stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
BIOMARIN PHARMACEUTICAL Hedge Fund Activity
We have seen 255 institutional investors add shares of BIOMARIN PHARMACEUTICAL stock to their portfolio, and 396 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- NORGES BANK added 5,487,201 shares (+268.5%) to their portfolio in Q4 2025, for an estimated $326,104,355
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 3,657,967 shares (-85.1%) from their portfolio in Q4 2025, for an estimated $217,392,978
- BLACKROCK, INC. removed 2,910,942 shares (-13.2%) from their portfolio in Q4 2025, for an estimated $172,997,283
- VIKING GLOBAL INVESTORS LP removed 2,285,243 shares (-27.5%) from their portfolio in Q4 2025, for an estimated $135,811,991
- DEEP TRACK CAPITAL, LP added 2,275,144 shares (+9153.3%) to their portfolio in Q4 2025, for an estimated $135,211,807
- VESTAL POINT CAPITAL, LP added 2,170,000 shares (+261.4%) to their portfolio in Q4 2025, for an estimated $128,963,100
- GOLDMAN SACHS GROUP INC removed 1,836,048 shares (-80.1%) from their portfolio in Q4 2025, for an estimated $109,116,332
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
BIOMARIN PHARMACEUTICAL Analyst Ratings
Wall Street analysts have issued reports on $BMRN in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Canaccord Genuity issued a "Buy" rating on 01/20/2026
- Bernstein issued a "Outperform" rating on 11/03/2025
- Barclays issued a "Overweight" rating on 10/28/2025
- Truist Securities issued a "Buy" rating on 10/28/2025
- Wells Fargo issued a "Overweight" rating on 10/28/2025
- Morgan Stanley issued a "Overweight" rating on 10/28/2025
To track analyst ratings and price targets for BIOMARIN PHARMACEUTICAL, check out Quiver Quantitative's $BMRN forecast page.
BIOMARIN PHARMACEUTICAL Price Targets
Multiple analysts have issued price targets for $BMRN recently. We have seen 11 analysts offer price targets for $BMRN in the last 6 months, with a median target of $84.0.
Here are some recent targets:
- Mohit Bansal from Wells Fargo set a target price of $75.0 on 02/18/2026
- Allison Bratzel from Piper Sandler set a target price of $84.0 on 02/06/2026
- Whitney Ijem from Canaccord Genuity set a target price of $98.0 on 01/20/2026
- Joon Lee from Truist Securities set a target price of $100.0 on 12/23/2025
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $60.0 on 12/22/2025
- Joseph Schwartz from Leerink Partners set a target price of $60.0 on 12/03/2025
- Paul Matteis from Stifel set a target price of $61.0 on 11/06/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
